The study aims to examine the association between SGLT2 inhibitors and the risk of late onset epilepsy in older adults.
Cohort study design conducted in a real-world setting
Analysis of patients using SGLT2 inhibitors
Follow-up to assess incidence of late onset epilepsy
SGLT2 inhibitor use correlated with a reduced risk of late onset epilepsy
Implications support etiology-specific therapeutic strategies.
Abstract
SGLT2i use was associated with reduced risk of LOE among selected patients, supporting its role in an etiology-specific therapeutic approach for older adults at risk of epilepsy.